Aligos Therapeutics Inc. have discovered two novel non-heteroaryldihydropyrimidine (HAP) class A capsid assembly modulators (CAM-A) – ALG-006746 and ALG-006780 – which are being developed for the treatment of hepatitis B virus (HBV) infection.